Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse.

Published byBaldwin Summers Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse."— Presentation transcript:

1 Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse cross-sectional view (left upper), sagittal view (right upper), and coronal view (left lower) before and after pioglitazone treatment. The transverse cross-sectional view at the L4–5 vertebral level was used in the measurement of sc and visceral fat areas. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

2 Figure 2. Index of hepatic insulin resistance (basal EGP × basal IRI) before and after 16 wk of pioglitazone treatment, where EGP is the endogenous glucose production (milligrams per kilogram FFM per minute) during the basal period, and IRI is the immunoreactive insulin concentration (microunits per milliliter). Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

3 Figure 3. Total body glucose MCR (milliliters per kilogram FFM per minute) during the first and second steps of the insulin clamp performed before and after 16 wk of pioglitazone treatment. *, P < 0.05; **, P < 0.01 (before vs. after pioglitazone). From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

4 Figure 4. Association between visceral fat area (left)/sc fat area (right) at the L4–5 vertebral level and hepatic insulin resistance (basal EGP × basal IRI) before and after 16 wk of pioglitazone treatment combined. Open symbols, Before pioglitazone; closed symbols, after pioglitazone. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

5 Figure 5. Association between visceral fat area (left)/sc fat area (right) at L4–5 vertebral level and total body glucose MCR during the first and second steps of the insulin clamp performed before and after 16 wk of pioglitazone treatment. Open symbols, Before pioglitazone; closed symbols, after pioglitazone. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

6 Figure 6. Relationship between hepatic insulin resistance (basal EGP × basal insulin concentration) and the fasting plasma FFA concentration in diabetic patients before (open symbols) and after (closed symbols) pioglitazone treatment. Sulfonylurea-treated subjects are indicated by the circles, and diet-treated subjects by the triangles. From: Effect of Pioglitazone on Abdominal Fat Distribution and Insulin Sensitivity in Type 2 Diabetic Patients J Clin Endocrinol Metab. 2002;87(6): doi: /jcem J Clin Endocrinol Metab | Copyright © 2002 by The Endocrine Society

Download ppt "Figure 1. MRI study demonstrating the change in visceral and sc abdominal fat area in a typical pioglitazone-treated patient. Each picture shows a transverse."

Similar presentations

Peter J Voshol, PhD Director of Disease Model Core Senior Research Associate: Integrative Physiology Disease Model Core Metabolic Phenotyping: which parameters.

Peter J Voshol, PhD Director of Disease Model Core Senior Research Associate: Integrative Physiology Disease Model Core Metabolic Phenotyping: which parameters.
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年１月 11 日 8:20-8:50 B 棟８階 カンファレンス室.

Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2007 年１月 11 日 8:20-8:50 B 棟８階 カンファレンス室.
Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:

Date of download: 7/5/2016 From: Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus:
Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.

Figure 1. Mass of rapid insulin secretory bursts and ApEn values in young and old subjects. Increased Disorderliness of Basal Insulin Release, Attenuated.
Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.

Figure 2. ROC curves for fasting values (A) and OGTT values (B) for detecting insulin resistance in PCOS women. Sensitivity is plotted against 1 − specificity.
Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.

Figure 1. Twenty-four-hour plasma ACTH concentrations in insomniacs (▪) and controls (○). The thick black line indicates the sleep recording period. The.
Figure 1. A schematic representation of the stress system

Figure 1. A schematic representation of the stress system
Circadian Rhythms of Women with Fibromyalgia1

Circadian Rhythms of Women with Fibromyalgia1
Figure 1. Schematic representation of TSHR

Figure 1. Schematic representation of TSHR
Fig. 1. Time line for investigations

Fig. 1. Time line for investigations
Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.

Fig. 1. Kaplan-Meir survival curves for Stoke Cushing's patients, with follow-up duration in years on the x-axis. Number of patients in each subgroup is.
From: Pharmacologic Therapy for Type 2 Diabetes Mellitus

From: Pharmacologic Therapy for Type 2 Diabetes Mellitus
From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.
Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs9939609 of the FTO gene. The P values are for the additive model.

Fig. 1. Mean BMI and BMI Z-score (se) of the children with AA, TA, and TT genotypes in rs of the FTO gene. The P values are for the additive model.
Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.
Fig. 1. Study enrollment and disposition of participants

Fig. 1. Study enrollment and disposition of participants
Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.

Figure 1. Illustrative 24-h serum LH concentration (IRMA) profiles and calculated LH secretory rates as determined by deconvolution analysis in one healthy.
Glucose tolerance testing. A

Glucose tolerance testing. A
Fig. 1. Left, Total ghrelin; right, octanoylated ghrelin

Fig. 1. Left, Total ghrelin; right, octanoylated ghrelin
Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Endocrinol. doi: /nrendo

Similar presentations

Ads by Google